Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DNM1 | Q05193 | 9/20 | 0.61 |
| ▸ | CA12 | O43570 | 2/20 | 0.61 |
| ▸ | CA1 | P00915 | 2/20 | 0.61 |
| ▸ | CA2 | P00918 | 2/20 | 0.61 |
| ▸ | CA3 | P07451 | 2/20 | 0.61 |
| ▸ | CA4 | P22748 | 2/20 | 0.61 |
| ▸ | CA6 | P23280 | 2/20 | 0.61 |
| ▸ | CA5A | P35218 | 2/20 | 0.61 |
| ▸ | CA7 | P43166 | 2/20 | 0.61 |
| ▸ | CA9 | Q16790 | 2/20 | 0.61 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.61 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.61 |
| ▸ | TSHR | P16473 | 2/20 | 0.61 |
| ▸ | LMNA | P02545 | 1/20 | 0.61 |
| ▸ | BLM | P54132 | 1/20 | 0.61 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28836736 | 1.00 | DNM1 (0.61) | DNM1CA12CA1CA2CA3 | |
| SCHEMBL28431058 | 1.00 | DNM1 (0.61) | DNM1CA12CA1CA2CA3 | |
| SCHEMBL28383397 | 1.00 | DNM1 (0.61) | DNM1CA12CA1CA2CA3 | |
| SCHEMBL345699 | 1.00 | — | — | |
| SCHEMBL3002135 | 1.00 | — | — | |
| SCHEMBL5554848 | 1.00 | DNM1 (0.61) | DNM1CA12CA1CA2CA3 | |
| SCHEMBL19037263 | 1.00 | DNM1 (0.61) | DNM1CA12CA1CA2CA3 | |
| SCHEMBL1695732 | 1.00 | — | — | |
| SCHEMBL7516444 | 1.00 | DNM1 (0.61) | DNM1CA12CA1CA2CA3 | |
| SCHEMBL7528554 | 1.00 | DNM1 (0.61) | DNM1CA12CA1CA2CA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025091971-A1 | SOLAR CELL AND PREPARATION METHOD THEREFOR, PHOTOVOLTAIC MODULE, SYSTEM, AND APPARATUS | 宁德时代新能源科技股份有限公司 | 2025-05-08 | — | — | WO | claimed |
| CN-119923165-A | Solar cell, preparation method thereof, photovoltaic module, system and power utilization device | 宁德时代新能源科技股份有限公司 | 2025-05-02 | — | — | CN | claimed |
| CN-120078891-A | Photodynamic targeted antibacterial microneedle patch and preparation method and application thereof | 中南大学 | 2025-06-03 | — | — | CN | disclosed |
| WO-2025091971-A1 | SOLAR CELL AND PREPARATION METHOD THEREFOR, PHOTOVOLTAIC MODULE, SYSTEM, AND APPARATUS | 宁德时代新能源科技股份有限公司 | 2025-05-08 | — | — | WO | disclosed |
| CN-119923165-A | Solar cell, preparation method thereof, photovoltaic module, system and power utilization device | 宁德时代新能源科技股份有限公司 | 2025-05-02 | — | — | CN | disclosed |
| CN-118806916-A | STING agonist prodrug, and synthetic method and application thereof | 浙江大学医学院附属第一医院(浙江省第一医院) | 2024-10-22 | — | — | CN | disclosed |
| CN-117263999-A | Camptothecin prodrugs and pharmaceutical compositions thereof | 天津和美奥康医药科技有限公司 | 2023-12-22 | — | — | CN | disclosed |
| CN-117186013-A | Protein degradation agent with abietic acid as hydrophobic group, preparation method, pharmaceutical composition and application thereof | 南开大学 | 2023-12-08 | — | — | CN | disclosed |
| CN-113214227-A | Heterocyclic compound and application thereof | 上海青玄生物科技有限公司 | 2021-08-06 | — | — | CN | disclosed |
| US-20170304235-A1 | LINEAR GUANIDINE DERIVATIVES, METHODS OF PREPARATION AND USES THEREOF | LEAD DISCOVERY SIENA S.R.L. (IT) | 2017-10-26 | — | — | US | disclosed |
| US-9442416-B2 | Image-forming apparatus, image-forming method, developing apparatus, and developing method | CANON KABUSHIKI KAISHA (JP) | 2016-09-13 | — | — | US | disclosed |
| WO-2009027971-A2 | ANTIMICROBIAL POLYMERS | H2Q WATER INDUSTRIES LTD. (IL) | 2009-03-05 | — | — | WO | disclosed |
| CN-1153604-C | Process for increasing extraction rate and back-extraction rate of anti-coagulation relative biological substance by adding halohydrocarbon | 中国科学院化工冶金研究所 | 2004-06-16 | — | — | CN | disclosed |
| CN-1353001-A | Process for increasing extraction rate and back-extraction rate of anti-coagulation relative biological substance by adding halohydrocarbon | CN ACAD INST CHEM METALLURGY (CN) | 2002-06-12 | — | — | CN | disclosed |
| EP-1083888-A1 | MULTIBINDING AGENTS THAT MODULATE PPARgamma AND RXR RECEPTORS | Advanced Medicine, Inc. (US) | 2001-03-21 | — | — | EP | disclosed |
| WO-1999063983-A9 | MULTIBINDING AGENTS THAT MODULATE PPARη AND RXR RECEPTORS | ADVANCED MEDICINE INC (US) | 2000-03-23 | — | — | WO | disclosed |
| WO-1999063983-A1 | MULTIBINDING AGENTS THAT MODULATE PPARη AND RXR RECEPTORS | ADVANCED MEDICINE, INC. (US) | 1999-12-16 | — | — | WO | disclosed |
| EP-0138504-B1 | STEROID DERIVATIVES | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1988-07-20 | — | — | EP | disclosed |
| US-4659516-A | ANTIESTROGENS | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1987-04-21 | — | — | US | disclosed |
| EP-0138504-A2 | Steroid derivatives | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1985-04-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170304235-A1 | LINEAR GUANIDINE DERIVATIVES, METHODS OF PREPARATION AND USES THEREOF | GMPS, CGAS, GDA | DNM1 822/4885CA12 4731/4885CA1 4824/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.